"When drug makers like Xtandi's manufacturer, Astellas Pharma, price gouge sick Americans," write the authors, "the U.S. government has a responsibility to end the exclusive patents that give them their profits." (Image: via Tecnofarma/industry)
Jan 26, 2022
What if we told you American taxpayers funded the invention of a highly successful prostate cancer medication, but if they need it, American prostate cancer patients are forced to pay far more than people living in similar nations?
The United States government should be using its investments in medical research and innovation to benefit all Americans, not just the shareholders at a few corporations.
That medication is called Xtandi, and Americans pay the highest prices in the world for it--a staggering $189,800 per year. That's up to five times more than patients living in Japan, Canada, the UK, France, Italy, Germany, Spain, or Australia.
The United States government should be using its investments in medical research and innovation to benefit all Americans, not just the shareholders at a few corporations.
When drug makers like Xtandi's manufacturer, Astellas Pharma, price gouge sick Americans, the U.S. government has a responsibility to end the exclusive patents that give them their profits.
A 2021 study estimated that 250,000 American men would be diagnosed with prostate cancer that year. Prostate cancer is the fifth most common cause of death among cancers--and it has the widest racial disparities of any form of cancer.
Black men in America experience the highest prostate cancer rates in the world.
For Hispanic or Latino men in the U.S., prostate cancer is the most common cancer diagnosis.
This means that the costs of Pharma's greed are borne primarily by men of color. Lowering Xtandi's outrageous price in the United States is a matter of racial justice.
And the rate of prostate cancer incidence increases with age, meaning that the price gouging takes a toll on Medicare's finances as well. From 2015 to 2019, Medicare spent $5.2 billion on Xtandi.
The Department of Health and Human Services is currently considering whether to allow the generic manufacturing of Xtandi, which could drop the price of a pill from $400 to $3 overnight.
Under the law, the Biden administration has the authority to act. All it needs is the courage to act.
Under the Bayh-Dole Act, federal agencies are granted "march-in rights." Essentially, if certain circumstances are met, the government can act ("march-in") and use its authority under the Bayh-Dole Act to grant a license to generic drug manufacturers to produce a drug in the United States--in this case, a generic version of Xtandi.
Charging American cancer patients up to five times more for a medication whose invention was 100% paid for by the American people and researched at a public American university...is not "reasonable."
One of those circumstances is if the original patent holder (or someone who licenses the drug, which is the case with Xtandi) fails to make the benefits of the invention "available to the public on reasonable terms."
We are asking the Biden administration to recognize that charging Americans up to five times more than what Astellas Pharma charges patients living in its own backyard, Japan, is not "reasonable."
Charging American cancer patients up to five times more for a medication whose invention was 100% paid for by the American people and researched at a public American university--in this case UCLA--is not "reasonable."
We are asking the Biden administration to ignore Big Pharma lobbyists, and prioritize saving American lives.
We are asking the Biden administration to help us build a system of drug pricing that is based on justice, not greed.
For years, the U.S. government has failed to exercise its clear authority under the law when it comes to the abusive pricing of taxpayer-funded drugs. It's time for the Biden administration to step up.
We are calling on Health and Human Services Secretary Xavier Becerra to do the right thing: allow generic manufacturing of Xtandi, and stop Big Pharma from price gouging American prostate cancer patients.
Join Us: News for people demanding a better world
Common Dreams is powered by optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place. We're hundreds of thousands strong, but every single supporter makes the difference. Your contribution supports this bold media model—free, independent, and dedicated to reporting the facts every day. Stand with us in the fight for economic equality, social justice, human rights, and a more sustainable future. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Ernie Powell
Ernie Powell is Senior Advisor on Grassroots Organizing at Social Security Works. Ernie's focus for over 40 years has been on public policy issues impacting older Americans. He is a nationally recognized expert on grassroots organizing and campaigns. He is 72 years old and resides in Los Angeles, CA.
Tiffany Cacy
Tiffany Cacy is a student at the University of California Los Angeles, studying Physiological Science and Global Health. She serves as the Internal Relations Executive of UCLA's Universities Allied for Essential Medicines chapter.
Ambika Verma
Ambika Verma is a recent alum from the University of California Los Angeles. She is currently working on MSF's Access to Medicine campaign during her gap year before matriculating at Yale University later this year to pursue her Masters in Public Health (MPH).
What if we told you American taxpayers funded the invention of a highly successful prostate cancer medication, but if they need it, American prostate cancer patients are forced to pay far more than people living in similar nations?
The United States government should be using its investments in medical research and innovation to benefit all Americans, not just the shareholders at a few corporations.
That medication is called Xtandi, and Americans pay the highest prices in the world for it--a staggering $189,800 per year. That's up to five times more than patients living in Japan, Canada, the UK, France, Italy, Germany, Spain, or Australia.
The United States government should be using its investments in medical research and innovation to benefit all Americans, not just the shareholders at a few corporations.
When drug makers like Xtandi's manufacturer, Astellas Pharma, price gouge sick Americans, the U.S. government has a responsibility to end the exclusive patents that give them their profits.
A 2021 study estimated that 250,000 American men would be diagnosed with prostate cancer that year. Prostate cancer is the fifth most common cause of death among cancers--and it has the widest racial disparities of any form of cancer.
Black men in America experience the highest prostate cancer rates in the world.
For Hispanic or Latino men in the U.S., prostate cancer is the most common cancer diagnosis.
This means that the costs of Pharma's greed are borne primarily by men of color. Lowering Xtandi's outrageous price in the United States is a matter of racial justice.
And the rate of prostate cancer incidence increases with age, meaning that the price gouging takes a toll on Medicare's finances as well. From 2015 to 2019, Medicare spent $5.2 billion on Xtandi.
The Department of Health and Human Services is currently considering whether to allow the generic manufacturing of Xtandi, which could drop the price of a pill from $400 to $3 overnight.
Under the law, the Biden administration has the authority to act. All it needs is the courage to act.
Under the Bayh-Dole Act, federal agencies are granted "march-in rights." Essentially, if certain circumstances are met, the government can act ("march-in") and use its authority under the Bayh-Dole Act to grant a license to generic drug manufacturers to produce a drug in the United States--in this case, a generic version of Xtandi.
Charging American cancer patients up to five times more for a medication whose invention was 100% paid for by the American people and researched at a public American university...is not "reasonable."
One of those circumstances is if the original patent holder (or someone who licenses the drug, which is the case with Xtandi) fails to make the benefits of the invention "available to the public on reasonable terms."
We are asking the Biden administration to recognize that charging Americans up to five times more than what Astellas Pharma charges patients living in its own backyard, Japan, is not "reasonable."
Charging American cancer patients up to five times more for a medication whose invention was 100% paid for by the American people and researched at a public American university--in this case UCLA--is not "reasonable."
We are asking the Biden administration to ignore Big Pharma lobbyists, and prioritize saving American lives.
We are asking the Biden administration to help us build a system of drug pricing that is based on justice, not greed.
For years, the U.S. government has failed to exercise its clear authority under the law when it comes to the abusive pricing of taxpayer-funded drugs. It's time for the Biden administration to step up.
We are calling on Health and Human Services Secretary Xavier Becerra to do the right thing: allow generic manufacturing of Xtandi, and stop Big Pharma from price gouging American prostate cancer patients.
Ernie Powell
Ernie Powell is Senior Advisor on Grassroots Organizing at Social Security Works. Ernie's focus for over 40 years has been on public policy issues impacting older Americans. He is a nationally recognized expert on grassroots organizing and campaigns. He is 72 years old and resides in Los Angeles, CA.
Tiffany Cacy
Tiffany Cacy is a student at the University of California Los Angeles, studying Physiological Science and Global Health. She serves as the Internal Relations Executive of UCLA's Universities Allied for Essential Medicines chapter.
Ambika Verma
Ambika Verma is a recent alum from the University of California Los Angeles. She is currently working on MSF's Access to Medicine campaign during her gap year before matriculating at Yale University later this year to pursue her Masters in Public Health (MPH).
What if we told you American taxpayers funded the invention of a highly successful prostate cancer medication, but if they need it, American prostate cancer patients are forced to pay far more than people living in similar nations?
The United States government should be using its investments in medical research and innovation to benefit all Americans, not just the shareholders at a few corporations.
That medication is called Xtandi, and Americans pay the highest prices in the world for it--a staggering $189,800 per year. That's up to five times more than patients living in Japan, Canada, the UK, France, Italy, Germany, Spain, or Australia.
The United States government should be using its investments in medical research and innovation to benefit all Americans, not just the shareholders at a few corporations.
When drug makers like Xtandi's manufacturer, Astellas Pharma, price gouge sick Americans, the U.S. government has a responsibility to end the exclusive patents that give them their profits.
A 2021 study estimated that 250,000 American men would be diagnosed with prostate cancer that year. Prostate cancer is the fifth most common cause of death among cancers--and it has the widest racial disparities of any form of cancer.
Black men in America experience the highest prostate cancer rates in the world.
For Hispanic or Latino men in the U.S., prostate cancer is the most common cancer diagnosis.
This means that the costs of Pharma's greed are borne primarily by men of color. Lowering Xtandi's outrageous price in the United States is a matter of racial justice.
And the rate of prostate cancer incidence increases with age, meaning that the price gouging takes a toll on Medicare's finances as well. From 2015 to 2019, Medicare spent $5.2 billion on Xtandi.
The Department of Health and Human Services is currently considering whether to allow the generic manufacturing of Xtandi, which could drop the price of a pill from $400 to $3 overnight.
Under the law, the Biden administration has the authority to act. All it needs is the courage to act.
Under the Bayh-Dole Act, federal agencies are granted "march-in rights." Essentially, if certain circumstances are met, the government can act ("march-in") and use its authority under the Bayh-Dole Act to grant a license to generic drug manufacturers to produce a drug in the United States--in this case, a generic version of Xtandi.
Charging American cancer patients up to five times more for a medication whose invention was 100% paid for by the American people and researched at a public American university...is not "reasonable."
One of those circumstances is if the original patent holder (or someone who licenses the drug, which is the case with Xtandi) fails to make the benefits of the invention "available to the public on reasonable terms."
We are asking the Biden administration to recognize that charging Americans up to five times more than what Astellas Pharma charges patients living in its own backyard, Japan, is not "reasonable."
Charging American cancer patients up to five times more for a medication whose invention was 100% paid for by the American people and researched at a public American university--in this case UCLA--is not "reasonable."
We are asking the Biden administration to ignore Big Pharma lobbyists, and prioritize saving American lives.
We are asking the Biden administration to help us build a system of drug pricing that is based on justice, not greed.
For years, the U.S. government has failed to exercise its clear authority under the law when it comes to the abusive pricing of taxpayer-funded drugs. It's time for the Biden administration to step up.
We are calling on Health and Human Services Secretary Xavier Becerra to do the right thing: allow generic manufacturing of Xtandi, and stop Big Pharma from price gouging American prostate cancer patients.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.